PX 1031

Drug Profile

PX 1031

Alternative Names: PX 103.1

Latest Information Update: 25 Jun 2009

Price : $50

At a glance

  • Originator Pharmexa
  • Class Cancer vaccines
  • Mechanism of Action ERBB 2 receptor antagonists; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 22 Jun 2009 Affitech AS has merged with Pharmexa to form Affitech A/S
  • 20 Dec 2006 Pharmexa and Ichor Medical Systems have entered into a collaborative agreement for PX 1031
  • 28 May 2003 Suspended - Phase-I/II for Breast cancer in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top